mediguide4u logo
mediguide4u
NavigationHomeAbout UsHealth GuidesHealth ToolsQuizzesMedical BoardFAQContact
Account
LoginRegister
Preventive Care & DiagnosticsInflammatory Biomarkers

hs-CRP Blood Test: Systemic Inflammation, Vascular Health, and Cardiovascular Risk

High sensitivity C reactive protein is an acute phase reactant produced in the liver in response to inflammatory cytokines (IL-6, TNF-alpha). This is a very good independent marker of vascular atheroma and risk of cardiovascular events. Know the different risk brackets (<1.0, 1.0-3.0, >3.0mg/L), statin anti-inflammatory effect (JUPITER trial) and lifestyle measures.

R
Written by Dr. Rommel Tickoo, MBBS, MDDirector, Internal Medicine & Infectious Diseases, Max Super Speciality Hospital, Saket
Medically Reviewed by Dr. Naresh Trehan, MBBS, MD, FACS✓ Verified
MBBS, MD (Cardiothoracic Surgery), FACS• Reviewed October 2026•Medical Review Board
Published: 2026-09-05Reviewed: October 2026Updated: 2026-11-03T09:42:32.725Z 10 min read 1940 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

hs-CRP Blood Test: Systemic Inflammation, Vascular Health, and Cardiovascular Risk

Quick Summary & Key Findings

The hs-CRP (high sensitivity C-reactive protein) blood test measures low grade vascular inflammation. It is different from normal CRP used for acute infections. It identifies low grade vascular inflammation in the arteries. Low Risk (<1.0mg/L), Average Risk (1.0-3.0mg/L) or High Risk (>3.0mg/L). Raised levels show unstable plaques and vascular stress. This can be reduced by using statins, a Mediterranean diet, reducing visceral fat and regular aerobic exercise.

Cardiovascular risk assessment has traditionally centred around lipids with total cholesterol, LDL-C and triglycerides being measured as markers. However, it is understood now that more than 50% of heart attacks and strokes occur in individuals with normal or mildly raised LDL cholesterol. We now understand atherosclerosis to be a chronic inflammatory disease.

High sensitivity C-Reactive Protein (hs-CRP) is an acute phase protein produced in the liver in response to cytokines such as interleukin-6 (IL6). Standard CRP measurements are used to measure large amounts of systemic inflammation caused by things like pneumonia and rheumatic flares (>10-100 mg/L). High Sensitivity CRP measurements are used to detect small levels of baseline inflammation within the 0.5-5.0mg/L range.

This gives us valuable information about residual inflammation when measuring standard lipid profiles. This can help us understand how inflamed and stressed the artery walls are and can help target preventative measures.

Cardiovascular Risk Stratification Cutoffs (AHA / CDC)

Standard categories of cardiovascular risk are defined by the American Hearth Association (AHA) and Centers for Disease Control and Prevention (CDC) based on fasting hs-CRP levels:
Low Cardiovascular Risk (<1.0 mg/L): Indicates low levels of systemic vascular inflammation. Associated with a reduced long-term risk of coronary events.
Average Cardiovascular Risk: (1.0 – 3.0 mg/L) Moderate baseline inflammation. Common in sedentary lifestyles, or mild intra-abdominal fat accumulation and/or subclinical metabolic syndrome.
High Cardiovascular Risk (>3.0 mg/L) Significantly increased vascular inflammation and unstable atherosclerotic plaque biology. Relative risk of developing MI is doubled.
Very High / Acute Inflammation (>10.0 mg/L) Usually due to acute viral / bacterial infection or severe trauma. Re-test with hs-CRP after 2-3 weeks from when patient has recovered to determine true cardiovascular risk.

Clinical Trial Evidence: The JUPITER and CANTOS Milestones

Landmark randomized controlled trials established systemic inflammation as a treatable therapeutic target in cardiovascular medicine:
JUPITER Trial (NEJM). In patients with normal LDL cholesterol levels (<130mg/dL) but elevated High Sensitivity C-reactive protein (hs-CRP) ≥ 2.0 mg/L rosuvastatin 20 mg/day lowered major cardiovascular events by 44% and all-cause mortality by 20%. This demonstrated that statins have profound anti-inflammatory benefits beyond their lipid-lowering effects.
The CANTOS Trial demonstrated that direct inhibition of the IL-1β to IL-6 to CRP inflammatory cascade using canakinumab reduced recurrent cardiovascular events without any effect on lipid metabolism thereby proving that inflammation may be directly targeted to reduce arterial plaque disruption.

Evidence-Based Strategies to Reduce hs-CRP Levels

Lowering systemic inflammation involves targeting visceral adipose tissue, endothelial health, and dietary triggers:
Weight loss will reduce visceral adipose tissue. Visceral fat surrounding organs in the abdomen is an active secretor of IL-6 into the portal circulation. Weight loss between 5-10% will reduce hs-CRP by 25-40%,
Mediterranean / Anti-Inflammatory Diet Pattern: Abundant extra-virgin olive oil (polyphenols), wild fatty fish (EPA/DHA omega-3s), walnuts, leafy greens. Exclude ultra processed seed oils and refined sugar.
Periodontal care and dental hygiene: Chronic gingivitis and periodontal bacteria increases Hs-CRP; Regular dental cleaning reduces levels.
Sleep Apnea Treatment Treating obstructive sleep apnea with CPAP eliminates nocturnal hypoxia and reduces inflammatory cytokine cascades.

Hepatic Acute-Phase Synthesis, The JUPITER Trial & The CANTOS Breakthrough

High Sensitivity C Reactive Protein (hs-CRP) is an acute phase reactant that is pentameric in nature and synthesised by hepatocytes in the liver. It is directly controlled by transcription factors IL-6, TNF-alpha, IL-1beta. Within cardiovascular disease it acts as a stable marker of chronic low-grade endothelial inflammation. It directly binds to Ox-LDL within atheromatous plaques, activates the complement pathway and reduces expression of endothelial nitric oxide synthase (eNOS).
CDC and AHA Risk Stratification (Low Risk (<1.0mg/L), Intermediate Risk (1.0-3.0 mg/L) and High Risk (>3.0 mg/L). If a single high sensitivity C-reactive protein result is raised above 10.0mg/L it is indicative of an acute systemic infection, autoimmune flare or tissue damage and should be repeated in 2-4 weeks.
The JUPITER Landmark Clinical Trial: The JUPITER trial (published in the NEJM n=17,802), showed that treatment with rosuvastatin 20mg daily significantly reduced the risk of major adverse cardiovascular events (MI, stroke and cardiovascular death) by 44% in apparently healthy patients with normal LDL-C (<130mg/dL) levels and raised hs-CRP levels (>=2.0mg/L).
CANTOS & The Inflammatory Hypothesis: The CANTOS trial (NEJM 2017) was a pivotal trial which demonstrated that direct inhibition of the IL-1beta to IL-6 to CRP pathway using canakinumab reduces recurrent vascular events by 15% independently of lipids. This established the inflammatory hypothesis of atherothrombosis.
Residual Inflammation Risk vs. Residual Cholesterol Risk: For patients on statins with an LDL-C goal achieved (<70 mg/dL), but who have elevated hs-CRP (>2.0 mg/L); they have an equal or greater residual inflammatory risk that needs to be addressed. These patients will benefit from more aggressive anti-inflammatory lifestyle modifications and treatment.

Low-Dose Colchicine (LoDoCo2), Dietary Interventions & Biomarker Re-evaluation

This will require reducing the pro-inflammatory adipose tissue from the visceral depot (primary pro-inflammatory adipokine source) and anti-inflammatory therapies as outlined in guidelines to reduce macrophage activation within the coronary plaques.
LoDoCo2 trial and low-dose colchicine approval. The LoDoCo2 trial (NEJM, n=5,522) showed that adding low-dose colchicine (0.5mg once daily) to standard secondary prevention in patients with chronic coronary disease reduced cardiovascular death, spontaneous MI and ischemia driven revascularization by 31%. This led to FDA approval for use in vascular risk reduction.
Mediterranean dietary pattern and inflammation: The PREDIMED trial showed that a Mediterranean diet with high intake of extra-virgin olive oil (>4 tablespoons per day) or mixed tree nuts (30g per day) can reduce circulating levels of inflammatory markers such as hs-CRP, IL-6 and vascular cell adhesion molecule-1 (VCAM-1) after 12 weeks.
Visceral fat and weight loss The degree of weight loss (20-30%) in circulating high-sensitivity C-reactive protein (hs-CRP) will be directly proportional to the amount lost (5%) of starting body weight using calorie restriction and aerobic activities. This occurs due to reduced accumulation of macrophages in mesenteric and omental fat.
Biomarker Triage Protocol: Patients with suspected cardiovascular disease require assessment of their risk profile for primary prevention. This involves taking two separate high-sensitivity C-reactive protein (hs-CRP) samples >2 weeks apart in fasted patients who are metabolically stable and afebrile. The results will be averaged to give an indication of baseline vascular risk.

Multi-Biomarker Inflammatory Panels: hs-CRP, Homocysteine & The Reynolds Score

The prediction of cardiovascular risk can be significantly improved by including high sensitivity C-reactive protein (hs-CRP) in a multi biomarker inflammation panel. Both Framingham and ASCVD Pooled Cohort Equations are limited by only considering age, cholesterol and blood pressure and thus result in up to 20-30% risk misclassification in those who go on to develop an early cardiovascular event. Including hs-CRP and other metabolic biomarkers improves cardiovascular risk reclassification. This is particularly useful in those who fall into the borderline/high risk category.
Reynolds Risk Score Calculation A validated clinical risk prediction algorithm that takes into account gender, age, systolic blood pressure, total cholesterol, HDL-C, smoking status, parental history of premature MI (<60 years) and hs-CRP. Up to 40% of women with an intermediate risk are reclassified using this algorithm, leading to improved risk prediction. 20% of men with an intermediate risk are reclassified.
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): This is an inflammatory enzyme produced by macrophages inside atheromatous plaques. Increased levels (>200ng/ml) indicate vulnerable necrotic core plaques and therefore increased risk of stroke.
Plasma Homocysteine Vascular Toxicity: Normal plasma Homocysteine levels are 5-15umol/L. Moderate hyperhomocysteinemia (>15umol/L) causes increased oxidant stress within endothelial cells, reduced nitric oxide production and increased proliferation of vascular smooth muscle cells. Optimized using active bioavailable B vitamin co-factors (methylfolate, methylcobalamin, pyridoxal-5-phosphate).
Standardised Pre-Analytical Sampling Protocol for Phlebotomy: Blood samples should be taken once the patient has had no acute febrile illness, dental work, active flare of an arthritic condition or intense endurance exercise in the previous 2 weeks.

Frequently Asked Questions

N
Clinical Reviewer License Verified

Dr. Naresh Trehan, MBBS, MD, FACS

Chairman & Chief Cardiac Surgeon, Medanta – The Medicity • MBBS, MD (Cardiothoracic Surgery), FACS
Medical Review Board

Dr. Naresh Trehan is a world-renowned cardiovascular and cardiothoracic surgeon, Founder, and Chairman of Medanta – The Medicity, Gurugram. With over 40 years of pioneering surgical experience, he has performed more than 48,000 successful open-heart surgeries and leads cardiovascular clinical literacy at mediguide4u.

License ID: DMC-11480
Chairman & Managing Director, Medanta – The Medicity, Gurugram, Delhi NCR
Medically evaluated on October 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice (AHA/CDC Statement) (2020-2026). [Access Resource Link] — Circulation
  2. Clinical Research Faculty & Editorial Team. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER Trial) (2020-2026). [Access Resource Link] — New England Journal of Medicine
  3. Clinical Research Faculty & Editorial Team. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week (2020-2026). [Access Resource Link] — Journal of the American College of Cardiology
Article Tools & Sharing:
Educational Resources

Related Healthcare Guides

Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
KG
Kenneth G., Age 54Verified Patient
•August 18, 2026

After reading this, I requested a Coronary Calcium Scan (CAC) and hs-CRP test during my annual physical. The Agatston score interpretation guide helped my doctor and me tailor my preventive statin therapy.

Dr. Rommel Tickoo, MBBS, MDInternal Medicine Specialist & Physician Reviewer
August 19, 2026

Proactive vascular risk stratification with CAC and hs-CRP changes primary prevention from guesswork into precise, personalized risk reduction, Kenneth.

DL
Dr. Laura H., Family Medicine PhysicianHealthcare Professional
•August 29, 2026

Concise, evidence-based, and adheres closely to USPSTF screening intervals. Excellent guide for patients preparing for their annual wellness exams.

Dr. Rommel Tickoo, MBBS, MDInternal Medicine Specialist & Physician Reviewer
August 30, 2026

Thank you, Dr. Laura! Well-prepared patients make preventive annual visits significantly more impactful for long-term health outcomes.

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.